Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kashiv Specialty Pharmaceuticals
Piscataway, New Jersey, United States
- Ownership
- Private
- Employees
- ~80
- Development stage
- Other
01
Overview
Kashiv Specialty developed a pipeline of 505(b)(2) drugs and complex generics, with lead programs in innovative oral and injectable drug delivery platforms. Its omalizumab biosimilar (ADL-018) achieved positive Phase 3 results in 2025, with other platform-based programs in neurology and endocrinology progressing toward clinical/commercial stages.
- Therapeutic areas
- ImmunologyNeurologyPulmonology
- Modalities
- Small moleculeBiologicPeptidesMonoclonal antibodyLong-acting injectableProtein
- Industry
- Biotech
02
Partnerships
Amneal PharmaceuticalsMS PharmaAlvotechAdvanz Pharma
Beyond the preview
Go deeper on Kashiv Specialty Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kashiv Specialty Pharmaceuticals.